经过其他治疗失败后, 一种实验性药物gotistobart在晚期肺癌患者中延长了生存期, 与化疗相比, 死亡风险降低了54%. An experimental drug, gotistobart, extended survival in advanced lung cancer patients after other treatments failed, with a 54% lower death risk compared to chemotherapy.

一种新的实验性治疗方法gotistobart在先进的状非小细胞肺癌患者中显著提高了生存率,这些患者之前已经用尽了前期治疗方法. A new experimental treatment, gotistobart, showed a significant survival advantage in patients with advanced squamous non-small cell lung cancer who had exhausted prior therapies. 在第三期PRESERVE- 003试验的非关键阶段,接受gotistobart的患者的寿命更长 - - 经过近15个月的中位生存期尚未达到 - - 与化疗治疗的10个月相比,死亡风险降低了54%. In a non-pivotal phase of the Phase 3 PRESERVE-003 trial, patients receiving gotistobart lived longer—median survival not yet reached after nearly 15 months—compared to 10 months with chemotherapy, reducing the risk of death by 54%. 以监管T细胞为对象的药物在12个月中存活率达到63.1%,而化疗的存活率为30.3%,具有类似的安全特征。 The drug, which targets regulatory T cells, achieved a 12-month survival rate of 63.1% versus 30.3% for chemotherapy, with a similar safety profile. 向2025年北美会议介绍了国际ASALC ASCO ACCO 2025 北美会议的结果,支持在正在进行的关键审判中进行进一步研究。 Results were presented at the IASLC ASCO 2025 North America Conference, supporting further study in the ongoing pivotal trial. FDA已授予该治疗快速通道认证。 The FDA has granted Fast Track Designation to the treatment.